Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment
- PMID: 12093086
- DOI: 10.1006/exnr.2002.7929
Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment
Abstract
alpha-Synuclein (alphaS), a presynaptic nerve terminal protein, is now known to be a major component of neuronal and glial cytoplasmic inclusions in alpha-synucleinopathies (Lewy body disease and multiple system atrophy). However, alphaS has not been identified in either neuronal or glial cytoplasm in formalin-fixed, paraffin-embedded tissue sections from the normal human brain. Previous studies have shown that pretreatment with either proteinase K or formic acid enhances alphaS immunoreactivity. The aim of the present study was, therefore, to study the effects of pretreatment with proteinase K and formic acid on alphaS immunoreactivity in vibratome sections of brain tissue taken from normal human subjects. In addition to presynaptic staining, alphaS immunostaining was recognized in neuronal perikarya in the pretreated sections; this immunoreactivity was more intense in sections taken from the deeper layers of the cerebral neocortex, the CA2/3 region of the hippocampus, and the substantia nigra. This pattern of alphaS expression coincides with the distribution of intraneuronal inclusions in alphaS transgenic animals as well as in human autopsy tissue taken from patients with Lewy body disease. Furthermore, intense immunoreactivity was also found in the cytoplasm of astrocytes and oligodendrocytes throughout the brain. These findings suggest that a significant amount of alphaS is also present in the neuronal and glial cytoplasm in the normal human brain.
Similar articles
-
Glial involvement in diffuse Lewy body disease.Acta Neuropathol. 2003 Feb;105(2):163-9. doi: 10.1007/s00401-002-0622-9. Epub 2002 Oct 25. Acta Neuropathol. 2003. PMID: 12536227
-
Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system.Brain Res. 2002 Jun 21;941(1-2):118-26. doi: 10.1016/s0006-8993(02)02643-4. Brain Res. 2002. PMID: 12031554
-
Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment.Lab Invest. 1998 Sep;78(9):1169-77. Lab Invest. 1998. PMID: 9759660
-
[Alpha-synucleinopathies].Neurologia. 2001 Apr;16(4):163-70. Neurologia. 2001. PMID: 11412709 Review. Spanish.
-
[Recent neuropathology of parkinsonian syndromes].Rev Neurol (Paris). 2003 May;159(5 Pt 2):3S11-8. Rev Neurol (Paris). 2003. PMID: 12773883 Review. French.
Cited by
-
Role of Specific Autoantibodies in Neurodegenerative Diseases: Pathogenic Antibodies or Promising Biomarkers for Diagnosis.Antibodies (Basel). 2023 Dec 8;12(4):81. doi: 10.3390/antib12040081. Antibodies (Basel). 2023. PMID: 38131803 Free PMC article. Review.
-
Lipopolysaccharide-induced blood brain barrier permeability is enhanced by alpha-synuclein expression.Neurosci Lett. 2013 Sep 13;551:23-7. doi: 10.1016/j.neulet.2013.06.058. Epub 2013 Jul 19. Neurosci Lett. 2013. PMID: 23876253 Free PMC article.
-
Alpha-synuclein expression modulates microglial activation phenotype.J Neurosci. 2006 Oct 11;26(41):10558-63. doi: 10.1523/JNEUROSCI.1799-06.2006. J Neurosci. 2006. PMID: 17035541 Free PMC article.
-
Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.J Biol Chem. 2010 Mar 19;285(12):9262-72. doi: 10.1074/jbc.M109.081125. Epub 2010 Jan 13. J Biol Chem. 2010. PMID: 20071342 Free PMC article.
-
Evaluation of alpha-synuclein immunohistochemical methods used by invited experts.Acta Neuropathol. 2008 Sep;116(3):277-88. doi: 10.1007/s00401-008-0409-8. Epub 2008 Jul 15. Acta Neuropathol. 2008. PMID: 18626651 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous